



JAN 03 2005

EFW

DOCKET NO.: AM1012009 US/WYNC-0324

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Deborah A. Evrard, et al.

Confirmation No.: 7478

Application No.: 10/659,174

Group Art Unit: 1625

Filing Date: September 10, 2003

Examiner: D. Margret M. Seaman

For: **Antidepressant Cycloalkylamine Derivatives Of Heterocycle-Fused Benzodioxans**

EXPRESS MAIL LABEL NO: EL 999282848 US
DATE OF DEPOSIT: December 29, 2004

EL999282848US

☒ MS Amendment ☐ MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REPLY TRANSMITTAL LETTER

- ☐ A Preliminary Amendment.
- ☒ A Reply Responsive to the Office Action Dated October 1, 2004.
- ☐ A Reply Supplemental to the Paper filed
- ☐ A Substitute Specification (pages 1 -) in clean form.
- ☐ A substitute specification (pages 1 -) with markings.
- ☐ An Abstract is enclosed.
- ☐ replacement sheets of drawings are enclosed comprising figures
- ☐ Request is hereby made to accept black and white photograph(s) in this case, as they are the only practicable medium for illustrating the claimed invention. One (1) set of black and white photographs comprising figure(s) is submitted herewith.
- ☐ Petition is hereby made to accept drawing(s)/photograph(s) in this case.

- ☐ Three (3) sets of color drawing(s)/photograph(s) and black and white photocopy that accurately depicts to the extent possible, the subject matter shown in the color drawing(s)/photograph(s), are enclosed, comprising figures
- ☐ An amendment to the first paragraph in that portion of the Brief Description of the Drawings is also enclosed herewith advising that the patent contains at least one drawing/photograph in color.
- ☐ A Certified Copy of each of the following applications: is enclosed.
- ☐ An Associate Power of Attorney is enclosed.
- ☐ Information Disclosure Statement.
- ☐ Attached Form 1449.
- ☐ A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.
- ☐ A Terminal Disclaimer is attached.
- ☒ Appendices as follows:

Waldinger MD, Olivier B. *Utility of selective serotonin reuptake inhibitors in premature ejaculation. Curr Opin Investig Drugs.* 2004 Jul;5(7):743-7;

Stearns V, Beebe KL, Iyengar M, Dube E. *Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA.* 2003 Jun 4;289(21):2827-34; .

Loprinzi CL *et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet.* 2000 Dec 16;356(9247):2059-63;

Brady KT, Sonne SC, Roberts JM. *Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiatry* 1995; 56:502-5;

Paxil CR® Prescribing Information

Young LR *et al., A therapeutic class evaluation of selective serotonin reuptake inhibitors*, by Tennessee Drug Utilization Review Program, U. of Tenn., Memphis, October 13, 1998;

Lexapro® package insert

Prozac® package insert

Boyer WF. *Potential indications for the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol* 1992 Jun; 6 Suppl 5:5-12

Janiri L, Gobbi G, Mannelli, *et al.* (1996). *Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics.* *Int Clin Psychopharmacol* 11:109-17

Perez V, Puigdemont D, Gilaberte I, Alvarez E, Artigas F. *Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors.* *J Clin Psychopharmacol.* (2001) Feb;21(1):36-45


- ☐ Other
- ☒ **No Additional Fee is Due.**
- ☐ Applicant(s) has previously claimed small entity status under 37 CFR § 1.27.
- ☐ Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as
- ☐ This application is no longer entitled to small entity status. It is requested that this be noted in the files of the U.S. Patent and Trademark Office.

				SMALL ENTITY		NOT SMALL ENTITY	
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	30	30 (20 MINIMUM)	0	\$25 EACH	\$	\$50 EACH	\$0
INDEP. CLAIMS	1	3 (3 MINIMUM)	0	\$100 EACH	\$	\$200 EACH	\$0
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$180	\$	\$360	\$0
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$60	\$	\$120	\$0
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$225	\$	\$450	\$0
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$510	\$	\$1020	\$0
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$795	\$	\$1590	\$0
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$1080	\$	\$2160	\$0
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$0)
<input type="checkbox"/> TERMINAL DISCLAIMER				\$65	\$	\$130	\$0
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE					\$		\$0

- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 23-3050.
- ☐ Please charge Deposit Account No. 23-3050 in the amount of .00. This sheet is attached in duplicate.

- ☐ Petition is hereby made under 37 CFR § 1.136(a) (fees: 37 CFR § 1.17(a)(1)-(4)) to extend the time for response to the Office Action of _____ to and through comprising an extension of the shortened statutory period of _____ month(s).
- ☒ The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to Deposit Account 23-3050. This sheet is provided in duplicate.

Date: December 29, 2004


Wendy A. Choi
Registration No. 36,697

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2004 WWC